Celon Pharma S.A. researchers will attend ERS Annual Congress that will be held from 6th to 10th of September 2014 in Munich. We will take this opportunity to present the latest data on innovative small-molecule inhibitors of JAK/STAT pathway and PI3Kd kinase which are being developed in our laboratories as potential therapeutics for asthma andRead more »
The 19th Congress of the European Hematology Association, during which Celon Pharma S.A. will be presenting the latest results of research on developing innovative PI3K-delta inhibitors, will be held on 12-15 June in Milan. We wish to encourage participants to see our poster presentation entitled: “Preclinical evaluation of a novel highly potent and selective PI3K-deltaRead more »
Our new publication on experimental oncology has just appeared! The article entitled “Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.” by Daria Zdzalik and co-workers was published in Journal of Cancer Research and Clinical Oncology and is freely available via PubMed/PMC.
Celon Pharma S.A. will participate in The European Cancer Congress 2013, which will be held in Amsterdam, the Netherlands. We will be presenting two posters at a session which is taking place on 29 September 2013: “Epithelial-mesenchymal transition confers resistance to FGFR inhibitors in gastric cancer cell line” and “Design and development of active andRead more »
On 15 May this year, the official award ceremony in a competition organised by the Polish Agency for Enterprise Development in cooperation with the Polish Society for Supporting Entrepreneurship took place. The goal of the competition was to honour modern and innovative business solutions. Celon Pharma received the main award in the “Innovative pharmaceutical andRead more »
Celon Pharma is going to present on VIII Multidisciplinary Conference on Drug Science (MKNOL) in Hotel Ossa & Spa near Rawa Mazowiecka. We’ve prepared two lectures: CPL-200-075, a novel potent renal sodium-glucose cotransporter 2 (SGLT2) inhibitor and Design and development of CPL-407-22 – novel, potent and selective JAK2 protein kinase inhibitor.
We have launched a Computer-assisted Drug Design Department. The unit’s task will be to support, in terms of bioinformatics and chemoinformatics, the process of designing active substances: developing methodology, conducting and analysing virtual screening, analysing the binding of active particles with proteins, estimating and assessing ADMET parameters, creating QSAR models. The Department has a wideRead more »